|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9644
|
|
pubmed:dateCreated |
2008-10-17
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
27
|
|
pubmed:volume |
372
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1174-83
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18757085-Aged,
pubmed-meshheading:18757085-Angioedema,
pubmed-meshheading:18757085-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:18757085-Benzimidazoles,
pubmed-meshheading:18757085-Benzoates,
pubmed-meshheading:18757085-Cardiovascular Diseases,
pubmed-meshheading:18757085-Cough,
pubmed-meshheading:18757085-Female,
pubmed-meshheading:18757085-Follow-Up Studies,
pubmed-meshheading:18757085-Humans,
pubmed-meshheading:18757085-Hypotension,
pubmed-meshheading:18757085-Kaplan-Meier Estimate,
pubmed-meshheading:18757085-Male,
pubmed-meshheading:18757085-Risk Reduction Behavior,
pubmed-meshheading:18757085-Single-Blind Method,
pubmed-meshheading:18757085-Therapeutic Equivalency
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
